Afraz, SajjadStevic, IvanMatino, DavideWen, JianpingAtkinson, HelenChan, Anthony K. C.Hortelano, Gonzalo2023-03-202023-03-202022Afraz, S., Stevic, I., Matino, D., Wen, J., Atkinson, H., Chan, A. K. C., & Hortelano, G. (2022). Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-19392-1http://nur.nu.edu.kz/handle/123456789/6966Hemophilia A is an X-linked recessive congenital bleeding disorder. Exogenous infusion of FVIII is the treatment of choice, and the development of immunoglobulins against FVIII (inhibitors) remains the major challenge in clinical management of the disease. Here, we investigated the effect of co-administration of FVIII with intravenous immunoglobulin (IVIG) on the development of inhibitors in previously untreated hemophilia A mice. A group of hemophilia A mice (C57BL/6FVIII−/−) received weekly injections of recombinant human FVIII (rFVIII) for twelve consecutive weeks while a second group received co-injections of rFVIII + IVIG. An in-house enzyme-linked immunosorbent assay (ELISA) was designed to detect antibodies to rFVIII. Every mouse in the first group developed antibodies to rFVIII. In contrast, mice treated with rFVIII + IVIG showed significantly lower antibody titers. Interestingly, when co-administration of IVIG was discontinued after 12 weeks in some mice (rFVIII continued), these mice experienced an increase in antibody titer. In contrast, mice that continued to receive rFVIII + IVIG retained significantly lower titers. In conclusion, prophylactic rFVIII co-administration with IVIG modulated the immune response to FVIII and resulted in decreased anti-FVIII antibody titer. These findings suggest that co-injection therapy with IVIG could potentially be effective in the management of hemophilia A patients at risk of inhibitor development.enAttribution-NonCommercial-ShareAlike 3.0 United StatesType of access: Open Accesshemophilia AArticle